Close this search box.


These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Medline Title Search (Dupuytren + Myofibroblast*)

Myofibroblasts are present locally in a number of fibrotic diseases, including Dupuytren disease.

Selected Publications

  • Badalamente MA, Hurst LC, Sampson SP. (1988). “Prostaglandins Influence Myofibroblast Contractility in Dupuytren’s Disease.” J Hand Surg Am 13 (6): 867–71. (PDF)
  • Badalamente MA, Stern L, Hurst LC. (1983). “The Pathogenesis of Dupuytren’s Contracture: Contractile Mechanisms of the Myofibroblasts.” The Journal of Hand Surgery 8 (3): 235–43. (PDF)
  • Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D. (1995). “TGF Beta and bFGF Synthesis and Localization in Dupuytren’s Disease (Nodular Palmar Fibromatosis) Relative to Cellular Activity, Myofibroblast Phenotype and Oncofetal Variants of Fibronectin.” The Histochemical Journal 27 (12): 1014–20. (PDF)
  • Degreef Ilse, De Smet Luc, Sciot Raf, Cassiman Jean-Jacques, Tejpar Sabine. (2009). “Immunohistochemical Evidence for Zic1 Coexpression with Beta-Catenin in the Myofibroblast of Dupuytren Disease.” Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery / Nordisk Plastikkirurgisk Forening [and] Nordisk Klubb for Handkirurgi 43 (1): 36–40. (PDF)
  • Delbruck A, Schroder H. (1994). “Fibroblast Gel Culture: A Model for Biochemical Investigations of Dupuytren’s Contracture.” In Berger A, Delbruck A, Brenner P, Hinzmann (Eds) Dupuytren’s Disease Pathobiochemistry and Clinical Management Springer-Verlag Berlin 1994, 139–50. (PDF)
  • Gokel JM, Hubner G. (1977). “Occurrence of Myofibroblasts in the Different Phases of Morbus Dupuytren (Dupuytren’s Contracture).” Beitr Pathol 161 (2): 166–75. (PDF)
  • Hinz Boris, Gabbiani Giulio. (2012). “The Role of the Myofibroblast in Dupuytren’s Disease: Fundamental Aspects of Contraction and Therapeutic Perspectives.” In Dupuytren’s Disease and Related Hyperproliferative Disorders, edited by Charles Eaton, M. Heinrich Seegenschmiedt, Ardeshir Bayat, Giulio Gabbiani, Paul Werker, and Wolfgang Wach. Berlin, Heidelberg: Springer Berlin Heidelberg. (PDF)
  • Hurst LC, Badalamente MA, Makowski J. (1986). “The Pathobiology of Dupuytren’s Contracture: Effects of Prostaglandins on Myofibroblasts.” J Hand Surg Am 11 (1): 18–23. (PDF)
  • Iqbal SA, Manning C, Syed F, Kolluru V, Hayton M, Watson S, Bayat A. (2012). “ Identification of Mesenchymal Stem Cells in Perinodular Fat and Skin in Dupuytren’s Disease: A Potential Source of Myofibroblasts with Implications for Pathogenesis and Therapy .” Stem Cells Dev 21 (4): 22–609. (PDF)
  • Kang Young-Mi, Choi Yun-Rak, Yun Chae-Ok, Park Jin-Oh, Suk Kyung-Soo, Kim Hak-Sun, Park Moon-Soo, Lee Byung-Ho, Lee Hwan-Mo, Moon Seong-Hwan. (2013). “Down-Regulation of Collagen Synthesis and Matrix Metalloproteinase Expression in Myofibroblasts from Dupuytren Nodule Using Adenovirus-Mediated Relaxin Gene Therapy.” J. Orthop. Res., November, 1–9. (PDF)
  • Karkampouna Sofia, Kloen Peter, Obdeijn Miryam C, Riester Scott M, van Wijnen Andre J, Kruithof-de Julio Marianna. (2015). “Human Dupuytren’s Ex Vivo Culture for the Study of Myofibroblasts and Extracellular Matrix Interactions.” Journal of Visualized Experiments, no. 98: 1–9. (PDF)
  • McCann B, Logan A, Belcher H, Warn A, Warn R. (1993). “ The Presence of Myofibroblasts in the Dermis of Patients with Dupuytren’s Contracture A Possible Source for Recurrence .” The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 18 (5): 656–61. (PDF)
  • McCann BG, Logan A, Belcher H, Warn A, Warn RM. (1993). “The Presence of Myofibroblasts in the Dermis of Patients with Dupuytren’s Contracture. A Possible Source for Recurrence.” Journal of Hand Surgery (Edinburgh, Scotland) 18 (5): 656–61. (PDF)
  • Murrell GAC, Francis MJO, Howlett CR. (1994). “Myofibroblasts Are Not Specific to Dupuytren’s Disease.” In Dupuytren’s Disease Pathobiochemistry and Clinical Management, 24–33. (PDF)
  • Musumeci Maria, Vadalà Gianluca, Russo Fabrizio, Pelacchi Federica, Lanotte Angela, Denaro Vincenzo. (2015). “Dupuytren’s Disease Therapy: Targeting the Vicious Cycle of Myofibroblasts?” Expert Opinion on Therapeutic Targets 19 (12): 1677–87. (PDF)
  • Rudolph R, Vande Berg J. (1991). “The Myofibroblast in Dupuytren’s Contracture.” Hand Clin 7 (4): 683–84. (PDF)
  • Shum DT, Pringle G, Hasegawa B, Botz JS, McFarlane RM. (1994). “Demonstration of Myofibroblasts Using a Novel Murine Monoclonal Antibody, 3C2G10.7 Raised from Proliferating Cells in Dupuytren’s Disease.” In Dupuytren’s Disease Pathobiochemistry and Clinical Management, 127–38. (PDF)
  • Staats Kim A, Wu Timothy, Gan Bing S, O’Gorman David B, Ophoff Roel A. (2016). “Dupuytren’s Disease Susceptibility Gene, EPDR1, Is Involved in Myofibroblast Contractility.” Journal of Dermatological Science 83 (2): 131–37. (PDF)
  • Tomasek JJ, Schultz RJ, Episalla CW, Newman SA. (1986). “The Cytoskeleton and Extracellular Matrix of the Dupuytren’s Disease ‘myofibroblast’: An Immunofluorescence Study of a Nonmuscle Cell Type.” J Hand Surg Am 11 (3): 365–71. (PDF)
  • Tomasek JJ, Schultz RJ, Haaksma CJ. (1987). “Extracellular Matrix-Cytoskeletal Connections at the Surface of the Specialized Contractile Fibroblast (Myofibroblast) in Dupuytren Disease.” The Journal of Bone and Joint Surgery. American Volume 69 (9): 1400–1407. (PDF)
  • Vande Berg JS, Gelberman RH, Rudolph R, Johnson D, Sicurello P. (1984). “Dupuytren’s Disease: Comparative Growth Dynamics and Morphology between Cultured Myofibroblasts (Nodule) and Fibroblasts (Cord).” J Orthop Res 2 (3): 247–56. (PDF)
  • Verhoekx Jennifer SN, Mudera Vivek, Walbeehm Erik T, Hovius Steven ER. (2013). “Adipose-Derived Stem Cells Inhibit the Contractile Myofibroblast in Dupuytren’s Disease.” Plastic and Reconstructive Surgery 132 (5): 1139–48. (PDF)
  • Verhoekx Jennifer SN, Verjee Liaquat S, Izadi D David, Chan James KK, Nicolaidou V Vicky, Davidson Dominique D, Midwood Kim S, Nanchahal Jagdeep J. (2013). “Isometric Contraction of Dupuytren’s Myofibroblasts Is Inhibited by Blocking Intercellular Junctions.” J Invest Dermatol , May. Nature Publishing Group. (PDF)
  • Verjee LS, Midwood K, Davidson D, Essex D, Sandison A, Nanchahal J. (2009). “ Myofibroblast Distribution in Dupuytren’s Cords: Correlation with Digital Contracture .” J Hand Surg Am 34 (10): 194–1785. (PDF)
  • Wong M, Mudera V. (2006). “Feedback Inhibition of High TGF-beta1 Concentrations on Myofibroblast Induction and Contraction by Dupuytren’s Fibroblasts.” J Hand Surg Br 31 (5): 473–83. (PDF)